AR and prostate carcinoma: It is a potent non-steroidal androgen receptor blocker known for its peripheral selectivity, attributed to poor blood–brain barrier penetration. While its primary usage is in cisgender men with prostate cancer, it has also been employed in the treatment of rare cases of peripheral precocious puberty in boys [77].